@entity4783 transdermal system compared with placebo reduces interference in functioning for XXXX .

@entity1 @entity1643 @entity158 @entity4783
UNASSIGNED: Abstract Objective: This study examines the efficacy of the @entity4783 transdermal system (BTDS) for reducing the interference of @entity158 on physical and emotional functioning associated with @entity1643 ( @entity1643 ). Methods: A post-hoc analysis used data from a randomized, placebo-controlled, double-blind trial of @entity1 with moderate-to-severe @entity1643 . The Brief Pain Inventory (BPI) measured @entity158 interference at screening, following a run-in period, and during the 12-week double-blind treatment phase. Statistical analyses examined treatment arm differences (BTDS vs placebo) for the following: BPI Interference subscale items and subscale scores at the trial end point (week 12); patterns of change in the Interference subscale scores over time; proportions of @entity1 indicating mild or no interference following treatment; and proportions of @entity1 showing improvement (30%, 50%, 2-point, or 4-point change in score from screening to week 12) for each item and subscale. Results: Mean scores for BPI Interference items and Interference subscale were significantly lower (ie, indicated less interference) for BTDS than for placebo (all P < 0.001). Treatment arm differences in Interference subscale scores emerged within 4 weeks of treatment. The BTDS @entity1 were significantly more likely to indicate mild/no interference on 5 of 7 Interference subscale items following treatment (P < 0.05). For most comparisons, BTDS @entity1 were significantly more likely to show criterion-level improvements in Interference item and subscale scores (P < 0.05 for differences). Discussion: Results indicate the efficacy of BTDS treatment, compared with placebo, for reducing the interference of @entity158 on physical and emotional functioning in @entity1 with moderate-to-severe @entity1643 . The advantage of BTDS was observed within 4 weeks of treatment, and was maintained throughout the 12-week treatment phase.
